PDS Biotechnology: 750K-share option awaits approval
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
PDS Biotechnology Corp granted Chief Medical Officer Kirk V. Shepard an option covering 750,000 shares of common stock on November 16, 2026, at an exercise price of $0.9241 per share. The option expires November 16, 2036. The grant is subject to stockholder approval of the 2026 Equity Incentive Plan under Nasdaq Marketplace Rule 5635(c), and the option cannot be exercised before approval. If approval is not obtained under the grant terms, Shepard must surrender the option for cancellation.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (Right to Buy) F1 | 750,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. The option was granted on November 16, 2026, subject to stockholder approval of the Issuer's 2026 Equity Incentive Plan under Nasdaq Marketplace Rule 5635(c). The option is not exercisable until stockholder approval has been obtained. Contingent upon stockholder approval, the shares subject to the option shall vest in equal monthly installments over four (4) years, beginning on December 16, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date. In the event stockholder approval is not obtained pursuant to the terms of grant, then the Reporting Person shall surrender the option to the Company for cancellation.
Key Figures
Key Terms
Nasdaq Marketplace Rule 5635(c) regulatory
vest financial
exercise price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does Kirk V. Shepard's PDSB option vest?
AI-generated analysis. How Rhea-AI works. Not financial advice.